Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease

Blardi, Patrizia; Lalla, A. De; Pieragalli, D.; Franco, V. De; Meini, Simone; Ceccatelli, L.; Auteri, Alberto

doi:10.1016/j.prostaglandins.2006.06.005

Cited by 16 publications

(20 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravenous infusion of PGI 2 and its analogs decreases thrombosis in dogs undergoing stent implantation in the common iliac vein (Seiji et al, 2009), in extracorporeal circuit of human patients undergoing hemofiltration (Kozek-Langenecker et al, 2003), and in patients with critical limb ischemia (Blardi et al, 2006). The mechanisms of PGI 2 effects may involve decreased expression of platelet activation markers such as platelet fibrinogen receptor and P-selectin, decreased platelet-leukocyte aggregation (Kozek-Langenecker et al, 2003), and decreased platelet granular release of serotonin (Blardi et al, 2006). PGI 2 also exerts its antithrombotic effects by disrupting some of the complex platelet aggregation reactions that occur during injury of vascular tissues.…”

Section: B the Prostacyclin Pathway And Blood Coagulationmentioning

confidence: 99%

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

2012

View full text Add to dashboard Cite

Section: B the Prostacyclin Pathway And Blood Coagulationmentioning

confidence: 99%

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

2012

View full text Add to dashboard Cite

“…A reduction of ADMA level, and by inference, of OS is expected to have therapeutic implications in vascular disease. Very recently Iloprost has shown to reduce ADMA levels in patients with Büerger disease (65). On the basis of the above reported tight correlation between ADMA and OS, this observation would support that Iloprost antioxidant properties might be the indirect consequence of a beneficial regulation of ADMA/NO pathway.…”

Section: Clinical and Experimental Evidences Of Antioxidative Effectmentioning

confidence: 72%

Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis

Erre¹,

Passiu²

2011

Reumatismo

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a dysimmune disorder of connective tissue characterized by disregulation of endothelial function and progressive tissue fibrosis. Although many studies have been carried out the pathogenesis of SSc is an issue still elusive. In a pioneer paper Murrel DF suggested oxidative stress (OS) as the keystone linking altered immune tolerance, endothelial injury and pro-fibrotic phenotype of SSc (1). In the last decade, this intriguing hypothesis has been strengthened by several firm evidences obtained at a cellular and molecular level. OS refers to a condition characterized by an imbalance in prooxidants and antioxidants, which results in damage to macromolecules..

show abstract

“…Plasma ADMA levels are elevated in patients admitted with acute coronary syndrome and falls rapidly with therapy to modify CVD risk factors 48 . In patients with PAD and critical limb ischemia, therapy with iloprost was associated with reduction in ADMA and clinical improvement in a small observational study 49 . It is not known if a reduction in plasma ADMA contributes to the established benefit of these therapies.…”

Section: Discussionmentioning

confidence: 99%

Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease

et al. 2010

View full text Add to dashboard Cite

Background Peripheral arterial disease (PAD) is associated with major cardiovascular morbidity and mortality. Abnormalities in nitric oxide metabolism due to excess of the NO synthase inhibitor asymmetric dimethylarginine (ADMA) may be pathogenic in PAD. We explored the association between ADMA levels and markers of atherosclerosis, function, and prognosis. Methods and Results 133 patients with symptomatic PAD were enrolled. Ankle brachial index (ABI), walking time, vascular function measures (arterial compliance and flow-mediated vasodilatation) and plasma ADMA level were assessed for each patient at baseline. ADMA correlated inversely with ABI (r = −0.238, p=0.003) and walking time (r = −0.255, p = 0.001), independent of other vascular risk factors. We followed up 125 (94%) of our 133 initial subjects with baseline measurements (mean 35 months). Subjects with ADMA levels in the highest quartile (>0.84 μmol/L) showed significantly greater occurrence of MACE compared to those with ADMA levels in the lower 3 quartiles (p = 0.001). Cox proportional-hazards regression analysis revealed that ADMA was a significant predictor of MACE, independent of other risk factors including age, gender, blood pressure, smoking history, diabetes and ABI (Hazard ratio = 5.1, p<0.001). Measures of vascular function, such as compliance, FMVD and blood pressure, as well as markers of PAD severity, including ABI and walking time, were not predictive. Conclusion Circulating levels of ADMA correlate independently with measures of disease severity and major adverse cardiovascular events. Agents that target this pathway may be useful for this patient population.

show abstract

Effect of iloprost on plasma asymmetric dimethylarginine and plasma and platelet serotonin in patients with peripheral arterial occlusive disease

Cited by 16 publications

References 42 publications

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn

Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis

Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease

Contact Info

Product

Resources

About